ArticleCancer management and research2026
Systemic Inflammation Response Index, Albumin, and Hemoglobin-Albumin-Lymphocyte-Platelet Score for Stage-Stratified Esophageal Cancer Discrimination: A Retrospective Case-Control Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammation- and nutrition-associated biomarkers have received increasing interest in esophageal cancer research. Nevertheless, the diagnostic value of the systemic inflammation response index (SIRI), albumin (ALB), and hemoglobin-albumin-lymphocyte-platelet (HALP) score across different pathological stages has not yet been fully clarified. We evaluated the performance of SIRI, ALB, and HALP, alone and in combination, for the auxiliary discrimination of esophageal cancer (EC), and examined their associations with clinicopathological characteristics in stage-stratified analyses. Methods: This retrospective study enrolled 168 esophageal cancer patients and 117 healthy controls (HC). SIRI and HALP were calculated preoperatively from routine hematological parameters. Cancer cases were divided into stage I/II (n = 32) and stage III/IV (n = 136) groups. ROC curve analysis evaluated the discriminatory efficacy of SIRI, ALB, HALP, and their combined model. The combined model was constructed using binary logistic regression incorporating SIRI, ALB, and HALP, and its discriminatory performance was evaluated by ROC analysis. Multivariable logistic regression adjusted for age and sex was performed, and bootstrap internal validation (1000 resamples) assessed model optimism. Results: Compared with healthy controls, patients with esophageal cancer exhibited significantly increased SIRI levels and significantly decreased ALB and HALP levels. The combined model achieved an AUC of 0.803 for distinguishing stage III/IV disease from healthy controls and 0.746 for stage I/II disease. SIRI was significantly associated with T stage and N stage. ALB with tumor length and T stage. HALP with smoking history and T stage. After adjustment for age and sex, HALP retained significance mainly in the all-cancer and stage III/IV analyses. Conclusion: SIRI, ALB, and HALP were associated with the occurrence and stage of esophageal cancer. Their combined model demonstrated improved discriminatory performance over single markers, particularly in stage III/IV disease, and retained additional value after adjustment for age and sex. These biomarkers may serve as convenient exploratory indicators for auxiliary assessment of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.